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Case Report
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A 2-year-old male with chronic kidney disease with secondary hyperparathyroidism developed hypercal-
cemia while receiving calcitriol, without achieving a serum parathyroid hormone concentration within the 
goal range. Cinacalcet 15 mg (1.2 mg/kg), crushed and administered via gastrostomy tube, was added to 
the patient’s therapy. This therapy was effective in achieving targeted laboratory parameters in our patient 
despite instructions in the prescribing information that cinacalcet should always be taken whole.
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INTRODUCTION
Abnormal bone and mineral metabolism and 
secondary hyperparathyroidism are well-de-
scribed consequences of chronic kidney disease 
(CKD), with progression to renal osteodystrophy, 
growth impairment, and vascular calcification if 
left untreated. Overcorrection is associated with 
adynamic bone disease.1 In addition to dietary 
phosphate binders, active vitamin D sterols 
are recommended to prevent bone disorders. 
Calcitriol (Rocaltrol, Roche Pharmaceuticals, 
Nutley, NJ) is the most commonly used form of 
vitamin D replacement in children who require 
renal replacement therapy, though its use can 
be limited by hypercalcemia.2 Alternatives as-
sociated with lower risk for hypercalcemia are 
available for adults, including doxercalciferol 
(Hectorol, Genzyme Corporation, Cambridge, 
MA), paricalcitol (Zemplar, Abbvie Inc, North 
Chicago, IL), and cinacalcet (Sensipar, Amgen, 
Thousand Oaks, CA), but optimal dosage regi-
mens in children receiving peritoneal dialysis 
(PD) are lacking.3 We aim to describe our use of 
an alternate administration method for cinacalcet 
in a child with CKD, hypercalcemia, and second-
ary hyperparathyroidism.
CASE REPORT
A 2-year-old, 10.3-kg, Caucasian male with a 
history of CKD presented to the pediatric clinic 
for evaluation for peritoneal dialysis after an 
emergency department admission for worsening 
vomiting and dehydration and was found to have 
stage 5 CKD. His past medical history was signifi-
cant for bilateral renal dysplasia, vesicoureteral 
reflux, posterior urethral valves, chronic vomit-
ing with failure to thrive, and CKD with anemia 
and secondary hyperparathyroidism.
At that time, he was receiving calcitriol 0.2 
mcg (0.02 mcg/kg) per gastrostomy tube (GT) 
twice daily and cinacalcet 6 mg (0.6 mg/kg) by 
GT. The 30-mg cinacalcet tablet (Sensipar) was 
crushed and mixed with 10 mL of water. A 5-mL 
portion of the solution was then administered 
for treatment of secondary hyperparathyroid-
ism. The cinacalcet product was prepared fresh 
each time it was administered and the remainder 
of the water/cinacalcet mixture was discarded. 
He was also receiving sodium and potassium 
phosphorous (2-mmoL phosphorus = ¼ packet 
250 mg twice daily), but adherence to this regi-
men was uncertain.
Laboratory results on this regimen were as 
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follows (see Table): serum calcium 11 mg/dL 
(normal, 8.5-10.5 mg/dL), phosphorus 3.3 mg/
dL (normal, 3.5-6.5 mg/dL), and parathyroid 
hormone (PTH) 596 pg/mL (goal, 200-300 pg/
mL). In an attempt to improve his management 
and simplify his medication regimen, cinacal-
cet was discontinued and calcitriol (Rocaltrol) 
was changed to a dose of 0.2 mcg (0.02 mcg/kg 
once daily. In addition, his enteral formula was 
changed from Similac PM 60/40 to half Similac 
Advance (Abbott, Abbott Park, IL) with half Simi-
lac PM 60/40 (Abbott) to increase the amount of 
phosphorous supplementation. At that time, both 
his weight and length were lower than the third 
percentile for his age.
At a 3-month follow-up visit, his serum calcium 
concentration remained elevated at 11 mg/dL. At 
this time his phosphorus concentration was with-
in the normal range at 6.1 mg/dL but his PTH 
concentration remained elevated at 368 pg/mL. 
Calcitriol was decreased to 0.15 mcg (0.012 mcg/
kg) per GT once daily. Two months following the 
calcitriol dose reduction, the calcium concentra-
tion had normalized (10 mg/dL); unfortunately, 
the PTH concentration remained elevated (513 
pg/mL). Phosphorous concentration remained 
in the low-normal range throughout this period 
(3.5 mg/dL). The patient was subsequently given 
15 mg (approximately 1.2 mg/kg) of cinacalcet 
extemporaneously as prepared above.
One month following the addition of cinacalcet 
the PTH concentration was within the goal range 
of 200 to 300 pg/mL, at 246 pg/mL, as were his 
calcium (9.6 mg/dL) and phosphorus (5.2 mg/
dL) concentrations. He subsequently required an 
increase in the dose of calcitriol to 0.2 mcg (0.015 
mcg/kg) owing to increasing PTH concentra-
tions. By this time the patient had demonstrated 
improvement in his growth, with a weight of 
13.2 kg.
DISCUSSION
Active vitamin D therapy, namely with cal-
citriol, is recommended by the KDOQI (Kidney 
Disease Outcomes Quality Initiative) Clinical 
Practice Guidelines for Bone Metabolism and 
Disease in Children with Chronic Kidney Disease 
for children with PTH serum concentrations that 
are above the target range for CKD stage.1 Our 
patient likely experienced calcitriol-associated 
hypercalcemia due to the increased gastrointes-
tinal tract absorption of calcium and phospho-
rus.2 The KDOQI guidelines recommend that 
for serum calcium concentrations greater than 
10.2 mg/dL, the calcitriol should be held until 
the serum calcium concentration is less than 9.8 
mg/dL and restarted at half of the previous dose. 
Unfortunately, this may not result in a serum PTH 
concentration within the goal range.1
For adults with CKD and secondary hyper-
parathyroidism, alternative options are available 
for active vitamin D therapy and PTH suppres-
sion. The vitamin D analogs paracalcitol and dox-
ercalciferol have a lesser effect on the absorption 
of calcium in the gastrointestinal tract but still 
Table. Patient Information and Laboratory Parameters
Presentation + 3 Months + 5 Months + 6 Months
Patient information
Height, cm 76.5 80 - 84.5
Weight, kg 10.3 12.4 12.7 13.9
Medication Calcitriol 
0.2 mcg BID
Calcitriol 
0.2 mcg
Calcitriol 
0.15 mcg
Calcitriol 
0.15 mcg
Cinacalcet 
6 mg (adherence 
uncertain)
Cinacalcet 15 mg
Laboratory value 
(institution normal for age)
PTH, pg/mL (10-65 pg/mL)* 596 368 513 246
Phosphorus, mg/dL (3.5-6.5 mg/dL) 3.3 6.1 3.5 5.2
Calcium, mg/dL (8.5-10.5 mg/dL) 11 11 10 9.6
Albumin, g/dL (3.1-4.7 g/dL) 3.9 3.3 3.2 3.1
Serum creatine, mg/dL (0.2-0.7 mg/dL) 3.61 5.11 4.49 3.57
BID, twice daily; ESRD, end-stage renal disease; PTH, parathyroid hormone
* ESRD goal, 200- 300 pg/mL
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reduce serum PTH concentrations.3–5 These are 
not available in formulations for patients who 
are unable to swallow a solid dosage form (as 
with our patient). Both alternatives are available 
as soft gelatin capsules, and though the contents 
can be evacuated with a syringe for subsequent 
administration, this strategy may be difficult and 
inexact.6,7 This technique does not allow lesser 
amounts than available dosage forms to be easily 
administered. While both paracalcitol and dox-
ercalciferol are available as intravenous formula-
tions, parenteral administration is not practical 
for PD patients, who are typically seen in clinic 
only 1 to 2 times per month.6,7 No information 
was found to support the use of the intravenous 
formulations enterally, though this could be an 
alternative option to investigate.
Though vitamin D therapy (calcitriol) has 
been shown to be effective in suppressing hy-
perthyroidism in end-state renal disease (ESRD) 
patients, resulting hypercalcemia is undesirable 
owing to potential for adverse effects and car-
diovascular disease.8 Cinacalcet is a calcimimetic 
that increases the sensitivity of the calcium-sens-
ing receptor on the parathyroid gland, leading 
to a decreased PTH concentration without a 
concomitant increase in serum calcium.3 It also 
increases the expression of vitamin D receptors 
on the thyroid gland, potentially allowing for a 
lower effective calcitriol dose.8 Cinacalcet has 
been studied in a small number of children and 
adolescents with ESRD and has been shown to 
result in decreased PTH without elevation in 
calcium or phosphorus.9–11 These studies have 
added cinacalcet to calcitriol therapy. Therefore, 
cinacalcet may be an additive option in children 
and adolescents with ESRD when the dose of 
calcitriol is limited by hypercalcemia (serum cal-
cium >10.2 mg/dL) and the PTH concentration 
is above the goal range. Combination therapy 
may also result in a decrease in phosphate binder 
requirement.10 The dose used in our patient was 
chosen from a review of the experience as pub-
lished by Platt and colleagues,9 where a wide 
initial dosing range of 0.4 to 1.4 mg/kg was used, 
and for simplicity of preparation by the patient’s 
caregiver.
Calcium should be closely monitored during 
therapy, and consideration for cinacalcet dis-
continuation or dose reduction should be given 
if the serum calcium concentration decreases to 
less than 8.4 mg/dL. Though used for only a 
short time period in these studies, cinacalcet has 
been generally well tolerated until the report of 
the recent death of a 14-year-old adolescent dur-
ing a cinacalcet clinical trial.12 The US Food and 
Drug Administration stopped all pediatric clini-
cal trials of cinacalcet and issued a drug safety 
communication until the cause of the death can 
be determined; causality has not been assigned.12
Liquid dosage forms of cinacalcet are not 
available. To administer 15 mg (approximately 
1.2 mg/kg), we instructed the parents to crush 
a 30-mg tablet, mix it with 10 mL of water, and 
administer 5 mL. The tablet was not to be halved 
before crushing, as it is not scored. Prescribing 
information indicates that the available tablet 
dosage form should be swallowed whole and 
not divided, though there is no evidence to 
demonstrate that crushing the tablet would result 
in drug inactivation. Administration of weight-
based cinacalcet to a group of 7 pediatric patients 
was described by Muscheites and colleagues,10 
whereby 30-mg tablets were ground into powder 
and re-pressed into tablets containing 2.5, 5, and 
7.5 mg. The resultant diminished serum PTH, 
phosphorus, and calcium concentrations were 
reassuring and indicated that cinacalcet could be 
safely crushed for administration in our patient. 
An additional study that evaluated single-dose 
cinacalcet in pediatric patients used a 15-mg 
dose, achieved by splitting a 30-mg tablet.13 The 
split tablet was weighed to confirm the appropri-
ate dose and administered with 90 ml of water; 
unfortunately, it is not clear in this study whether 
the split tablet was subsequently crushed or was 
swallowed whole.
We believe that the GT administration of cina-
calcet after crushing has no deleterious results on 
the medication’s effectiveness. This is supported 
by the normalization of our patient’s laboratory 
parameters (serum PTH and calcium within goal 
range). The normalization was temporally asso-
ciated with cinacalcet administration via GT in 
the absence of other interventions. More data are 
needed to determine the role of cinacalcet therapy 
in children with CKD and if GT administration 
results in outcomes similar to administration of 
the solid tablet form. Our experience with this 
case supports the use of cinacalcet when crushed 
for GT administration.
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